LifeSci Capital Downgrades Mereo BioPharma Group to Market Perform

Benzinga · 1d ago
LifeSci Capital analyst Cory Jubinville downgrades Mereo BioPharma Group (NASDAQ:MREO) from Outperform to Market Perform.